Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SFDA Drafts New Fast Track Procedures For Drug Registration

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China regulators released a streamlined draft drug approval rule this month that would provide for faster approval of four categories of new drugs. The State Food and Drug Administration finished collecting public comments on the rule Oct. 15

You may also be interested in...



Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy

Beta Pharma is likely to see $50 million in the first year of sales for icotinib, the first NCE cancer drug developed in China.

China Issues Fast-Track Registration For Drugs To Balance Innovation And Risk

Drugs and APIs in four categories now can gain approval in 120 days, down from 150.

China Issues Fast-Track Registration For Drugs To Balance Innovation And Risk

Drugs and APIs in four categories now can gain approval in 120 days, down from 150.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC065697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel